Achaogen (AKAO) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Needham & Company Downgrades Achaogen (AKAO) to Hold
March 16, 2016 6:52 AM EDTNeedham & Company downgraded Achaogen (NASDAQ: AKAO) from Buy to Hold.
Analyst Alan Carr commented, "Achaogen provided a 4Q15 update yesterday. Enrollment in plazomicin Phase 3 CRE trial remains slow. Mgmt has concluded that a superiority trial in this indication is not feasible and will... More
